United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - tin 1 [hp_x] in 1 g - directions: for topical use only. use: temporary relief of headache.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - tin 5 [hp_x] in 1 g - directions: for topical use only. use: temporary relief of headache.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - tin 1 [hp_x] in 1 g - directions: for topical use only. use: temporary relief of headache.

United States - English - NLM (National Library of Medicine)

boiron - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - wet cough* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - wet cough* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - paroxetine hydrochloride hemihydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - paroxetine hydrochloride 22.22mg equivalent to 20 mg paroxetine - tablet - 20 mg - active: paroxetine hydrochloride 22.22mg equivalent to 20 mg paroxetine excipient: acetone calcium hydrogen phosphate colloidal silicon dioxide isopropyl alcohol magnesium stearate methacrylic acid copolymer purified talc sodium starch glycolate titanium dioxide - major depressive disorder paxtine is indicated for the treatment of major depressive disorder (mdd). paxtine is indicated for the prevention of relapse and also recurrence of further depressive episodes

European Union - English - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastic agents - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levonorgestrel - tablets - levonorgestrel 1.5 mg - levonorgestrel - levonorgestrel - emergency contraseptive.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin-c is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). prolastin-c increases antigenic and functional (anti-neutrophil elastase capacity, anec) serum levels and antigenic lung epithelial lining fluid levels of alpha1 -pi. limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c are not available. - prolastin-c is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c is contraindicated in: - iga deficient patients w